Stocklytics Platform
Genprex
GNPX57
$0.26arrow_drop_up1.24%$0.00
NASDAQ - As of Apr 13, 5:42 PM EDT Market Closed
High Growth
Penny Stock
GNPX57

$0.26

arrow_drop_up1.24%

Performance History

arrow_drop_down88.65%

(-$2.08 )

Stocklytics logo
Key Stats
Open$0.27
Prev. Close$0.26
EPS-10.69
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$6.43M
PE Ratio-
LOWHIGH
Day Range0.26
0.28
52 Week Range0.22
15.20
Ratios
P/B Ratio1.90
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %-29.99%
EBITDA Margin %-
ROE %-325.11%
EPS-10.69

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Eli Lilly & Co
LLY84
Price$732.41
Perf. (24h)arrow_drop_up1.59%$11.50
Market Cap$657.82B
UnitedHealth Group
UNH69
Price$599.47
Perf. (24h)arrow_drop_up1.21%$7.22
Market Cap$553.56B
Johnson & Johnson
JNJ61
Price$151.73
Perf. (24h)arrow_drop_up2.04%$3.03
Market Cap$397.30B
AbbVie
ABBV67
Price$175.05
Perf. (24h)arrow_drop_up0.77%$1.35
Market Cap$309.65B

About Genprex (GNPX)

Genprex Inc (GNPX) is a biopharmaceutical company focused on developing targeted molecular therapies for the treatment of cancer. The company's lead product candidate is REQORSA™ immunogene therapy, which is being evaluated in clinical trials for the treatment of non-small cell lung cancer (NSCLC). REQORSA™ is designed to inhibit the signaling pathways that contribute to cancer cell growth and survival, potentially leading to improved patient outcomes. Genprex is also developing a diabetes gene therapy program, which aims to provide a long-term solution for patients with insulin-dependent diabetes.
GNPX stock has shown significant volatility in its price history. Over the past year, the stock has traded in a range of $1.50 to $9.00 per share. The current market capitalization of Genprex Inc is approximately $250 million. The company has a PEG ratio of 0.80, indicating that the stock may be undervalued compared to its expected earnings growth. When comparing Genprex Inc to its industry peers, it is important to note that the company operates in the biopharmaceutical sector, which is known for its high levels of innovation and risk. Investors should carefully consider these factors when evaluating the stock's potential for future growth.
Show more
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. John Rodney Varner
Headquarters
Austin
Employees
28
Exchange
NASDAQ
add Genprex to watchlist

Keep an eye on Genprex

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the 52-week high and low for Genprex (GNPX)?

For Genprex (GNPX), the 52-week high is $15.2, which is 5.6K% from the current price. The 52-week low is $0.23, the current price is 17.4% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

What is Genprex 's (GNPX) price per share?

The current price per share for Genprex (GNPX) is $0.27. The stock has seen a price change of $0 recently, indicating a 1.25% change. This reflects the stock's recent market performance and investor sentiment.
help

Is Genprex (GNPX) a growth stock?

Genprex (GNPX) has shown an average price growth of -1.65% over the past three years. It has received a score of 88 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Genprex as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Genprex (GNPX) stock price performance year to date (YTD)?

As of the latest data, Genprex (GNPX) has a year-to-date price change of -68.71%. Over the past month, the stock has experienced a price change of -22.75%. Over the last three months, the change has been -63.5%. Over the past six months, the figure is -22.03%. Looking at a longer horizon, the five-year price change stands at -99.7%.
help

Is Genprex (GNPX) a profitable company?

Genprex (GNPX) has a net income of -$30.86M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$31.08M. Furthermore, the EBITDA is -$22.82M.
help

What is the market capitalization of Genprex (GNPX)?

Genprex (GNPX) has a market capitalization of $6.44M. The average daily trading volume is 0.27, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level